Source: Eur Respir J 2015; 45: 305-307
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Ricard Jean-Damien, Messika Jonathan. Low-dose corticosteroids during severe community-acquired pneumonia: end of the story. Eur Respir J 2015; 45: 305-307

Member's Comments

No comment yet.

Related content which might interest you: Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Efficacy of corticosteroids in hospital treated community-acquired pneumonia Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008 Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016 Corticosteroids for community-acquired pneumonia: are we still there? Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment Year: 2019 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Effect of corticoids on the clinical course and outcome of severe community-acquired pneumonia Source: Annual Congress 2004 - SARS and other lower respiratory tract infections Year: 2004 Treatment of severe community-acquired pneumonia: new horizons Source: International Congress 2014 – Advances in managing acute respiratory failure Year: 2014 Critical illness-related corticosteroid insufficiency and community-acquired pneumonia: back to the future! Source: Eur Respir J 2008; 31: 1150-1152 Year: 2008 Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 Acute bronchiolitis in hospitalised patients: inappropriate use of corticosteroids Source: Eur Respir J 2005; 26: Suppl. 49, 29s Year: 2005 Should steroids be used in community-acquired pneumonia? Pro argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017 Oral antibiotics prior to hospitalisation for community-acquired pneumonia Source: Eur Respir J 2008; 31: 478-479 Year: 2008 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007